These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27441415)

  • 1. Frequent PIK3CA activating mutations in nipple adenomas.
    Liau JY; Lee YH; Tsai JH; Yuan CT; Chu CY; Hong JB; Sheen YS
    Histopathology; 2017 Jan; 70(2):195-202. PubMed ID: 27441415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin.
    Liau JY; Tsai JH; Huang WC; Lan J; Hong JB; Yuan CT
    Hum Pathol; 2018 Mar; 73():59-65. PubMed ID: 29241739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
    Schönleben F; Qiu W; Allendorf JD; Chabot JA; Remotti HE; Su GH
    J Gastrointest Surg; 2009 Aug; 13(8):1510-6. PubMed ID: 19440799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent PIK3CA-activating mutations in hidradenoma papilliferums.
    Liau JY; Lan J; Hong JB; Tsai JH; Kuo KT; Chu CY; Sheen YS; Huang WC
    Hum Pathol; 2016 Sep; 55():57-62. PubMed ID: 27184479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.
    Chang LC; Chiu HM; Shun CT; Liang JT; Lin JT; Chen CC; Lee YC; Wu MS
    BMC Gastroenterol; 2014 Dec; 14():221. PubMed ID: 25551625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT; Lu YY; An YX; Wang X; Zhao QC
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
    Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
    Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum.
    Kaji E; Kato J; Suzuki H; Akita M; Horii J; Saito S; Higashi R; Ishikawa S; Kuriyama M; Hiraoka S; Uraoka T; Yamamoto K
    J Gastroenterol Hepatol; 2011 Mar; 26(3):599-607. PubMed ID: 21332555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations.
    Agaimy A; Stoehr R; Vieth M; Hartmann A
    Am J Surg Pathol; 2010 Nov; 34(11):1663-71. PubMed ID: 20962618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
    Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
    Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
    Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
    Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation.
    Lee H; Lee JH; Kim DK; Choi IJ; Hwang I; Kang YN; Kim S
    Int J Med Sci; 2015; 12(4):349-53. PubMed ID: 26019684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
    Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
    Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.
    Zhou L; Baba Y; Kitano Y; Miyake K; Zhang X; Yamamura K; Kosumi K; Kaida T; Arima K; Taki K; Higashi T; Imai K; Hashimoto D; Yamashita Y; Chikamoto A; Beppu T; Tan X; Baba H
    Med Oncol; 2016 Apr; 33(4):32. PubMed ID: 26927447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.